Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Fendler on Rationale for Creating the 68Ga-PSMA-11 PET in Prostate Cancer

April 4th 2020

Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.

Immune Correlates May Indicate Responsiveness to Ipilimumab in mCRPC

April 3rd 2020

A subset of patients with metastatic castration-resistant prostate cancer who have low tumor mutational burden may benefit from checkpoint inhibition with ipilimumab if the tumor has a high density of CD8-positive T cells and increased interferon-interferon gamma signaling.

Dr. Gomella on Potential Impact of Targeted Therapy Approvals on Genetic Testing in Prostate Cancer

April 3rd 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the potential impact of targeted therapy approvals on the use of genetic testing in prostate cancer.

Novel Hormonal Agents Foster New Approaches in Nonmetastatic CRPC

April 1st 2020

Nonmetastatic castration-resistant prostate cancer is a more recently defined clinical state of prostate cancer, for which several approved drugs are now available.

PARP Investigations Continue on Path Toward Precision Medicine in Prostate Cancer

March 31st 2020

The use of PARP inhibitors against DNA damage repair alterations in prostate cancer is the first display of the potential for widespread precision medicine in the field.

Ep. 14: Emerging Agents in the Management of Prostate Cancer

March 31st 2020

Ep. 13: Avoiding Repeat Lines of AR-Targeted Therapy in mCRPC

March 31st 2020

Ep. 12: What is Radium 223

March 31st 2020

Ep. 11: Factors in Selecting Therapy for mCRPC

March 31st 2020

Ep. 10: How Has the mCRPC Treatment Landscape Changed?

March 31st 2020

Ep. 9: Neurological AEs and Quality of Life in Treating nmCRPC

March 31st 2020

Ep. 8: Selecting Optimal AR-Targeted Therapy for nmCRPC

March 31st 2020

Ep. 7: Current Treatment and Imaging Options for nmCRPC

March 31st 2020

Ep. 6: Identifying Nonmetastatic CRPC

March 31st 2020

Ep. 5: Ongoing CSPC Clinical Trials

March 31st 2020

Ep. 4: Currently Approved Therapies for Metastatic CSPC

March 31st 2020

Ep. 3: Addressing Cardiovascular Risk and Events in CSPC

March 31st 2020

Ep. 2: Identifying and Monitoring Testosterone Levels in CSPC

March 31st 2020

Ep. 1: Initiating Therapy for CSPC

March 31st 2020

Dr. Oh on Results From the PRINT Trial in mCRPC

March 31st 2020

William K. Oh, MD, sheds light on the results of the phase II PRINT trial in metastatic castration-resistant prostate cancer.